Holen Sie sich die Stockscreener-App
0.6702
42.72%
-0.4998
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BCLI?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.17
Offen:
$0.71
24-Stunden-Volumen:
379.09K
Relative Volume:
0.30
Marktkapitalisierung:
$6.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.63M
KGV:
-1.5586
EPS:
-0.43
Netto-Cashflow:
$-21.84M
1W Leistung:
-44.15%
1M Leistung:
-45.07%
6M Leistung:
-68.54%
1J Leistung:
-87.55%
1-Tages-Spanne:
$0.67
$0.75
1-Wochen-Bereich:
$0.67
$1.28
52-Wochen-Spanne:
$0.67
$6.00
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Firmenname
Brainstorm Cell Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BCLI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.6702 | 12.00M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-02-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-11-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-12-19 | Bestätigt | Maxim Group | Buy |
| 2015-12-22 | Bestätigt | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Aktie (BCLI) Neueste Nachrichten
What drives Brainstorm Cell Therapeutics Inc. stock priceHigh-margin investment plays - Autocar Professional
Is Brainstorm Cell Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com
What analysts say about Brainstorm Cell Therapeutics Inc. stockFastest return on investment - jammulinksnews.com
Brainstorm Cell Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - jammulinksnews.com
BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down - MSN
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time' - Stocktwits
Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement - Benzinga
Brainstorm Cell Therapeutics Faces Nasdaq Delisting Notice - TipRanks
Brainstorm Cell Therapeutics to Delist From Nasdaq - MarketScreener
BrainStorm Cell Therapeutics shares fall 51.20% after-hours after Nasdaq delisting notification. - AInvest
BrainStorm Cell Therapeutics stock delisted from Nasdaq, trades on OTCQB - AInvest
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB By Investing.com - Investing.com India
BrainStorm Cell Therapeutics to delist from Nasdaq, move to OTCQB - Investing.com
BrainStorm Cell Faces Nasdaq Exit: What the OTCQB Switch Means for Investors and NurOwn Program - Stock Titan
BrainStorm Receives 3 Million NIS Grant from Israel's Office of the Chief Scientist - AOL.com
Why Brainstorm Cell Therapeutics Inc. stock attracts strong analyst attentionFree Deep Market Trend Analysis - Newser
What makes Brainstorm Cell Therapeutics Inc. stock price move sharplyFree Stock Trading Community - Newser
How Brainstorm Cell Therapeutics Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn By Investing.com - Investing.com South Africa
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data - BioSpace
BTCS, BrainStorm Cell, Moderna - TradingView
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness - The Malaysian Reserve
BrainStorm Cell Therapeutics: A Rare Disease Breakthrough on the Brink of Regulatory Approval - AInvest
NurOwn's Regulatory Crossroads: Why BrainStorm Cell Therapeutics (BCLI) Could Be Poised for a Turnaround - AInvest
FDA to review citizen petition on BrainStorm’s ALS therapy NurOwn - Investing.com
BCLI: Citizen's Petition Filed Requesting the FDA Approve NurOwn - Smartkarma
ALS Community Files Citizens’ Petition asking FDA to Approve NurOwn Stem Cell Therapy - Asbury Park Press
5 Best Stem Cell Companies to Invest In (July 2025) - Securities.io
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Press Release Service: Gene and Cell Therapies Targeting CNS Disorders Market Research 2025-2035 | Novartis, BrainStorm Cell Therapeutics, Neuroplast, Rapa Therapeutics, and Longeveron Driving InnovationsResearchAndMarkets.com - CRISPR Medicine News
NurOwn's Next Act: BrainStorm Cell Therapeutics' Share Resale and the ALS Trial Gamble - AInvest
9 of 10 NurOwn-treated ALS patients surpass five-year survival - ALS News Today
Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033 - Straits Research
Brainstorm Cell's NurOwn Study Data Shows 90% Survival Rate In ALS Patients, Stock Up In Pre-Market - Nasdaq
Encouraging Survival Data Revealed for BrainStorm's NurOwn in ALS Study (BCLI) | BCLI Stock News - GuruFocus
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® – Company AnnouncementFT.com - Financial Times
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Sell at Wall Street Zen - Defense World
Corestemchemon preps US BLA filing for stem cell ALS therapy - BioWorld MedTech
Brainstorm taps Minaris to produce NurOwn for Phase 3b trial - ALS News Today
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Finanzdaten der Brainstorm Cell Therapeutics Inc-Aktie (BCLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Brainstorm Cell Therapeutics Inc-Aktie (BCLI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):